SUMMARY

The main conclusions derived from the ASH annual meeting in San Diego, CA, last year regarding myeloproliferative neoplasms are:

  • Single and multi-hit TP53 mutations need to be included in the risk stratification of MPN. Multi-hit TP53 MPN belong in the ICC category of “myeloid neoplasms with mutated TP53” and need to be considered as a hematologic emergency.
  • Timing of HSCT in MF depends of the disease risk category; MTSS risk score, presence of TP53 mutation and response to ruxolitinib.
  • Promising new treatments beyond JAKi for MF are the MDM2 inhibitor navtemadlin, the PIM1 kinase inhibitor nuvisertib, and cellular therapy with Tregs.
  • In advanced systemic mastocytosis, OS is superior in TKI treated patient. MARS-R is a novel risk score specifically looking at OS and leukaemia free survival in TKI treated patients.
  • Asciminib front-line treatment for CP-CML is superior to first- and second-line TKI in both efficacy and safety/tolerability.

(BELG J HEMATOL 2025;16(1):12–8)